期刊
CURRENT DRUG TARGETS
卷 19, 期 16, 页码 1933-1942出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450119666180219120534
关键词
NF-kappa B; IKK beta; inflammation; cancer; proteasome inhibitor; N-acylhydrazone
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)
- Instituto Nacional de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR, BR) [465.249/2014]
Background: Nuclear factor kappa B (NF-kappa B) comprises a family of proteins that act as transcription factors promoting the expression of many genes. Activation of NF-kappa B biochemical cascades is associated with the regulation of innate and adaptive immune responses and inflammation, among other physiological responses. However, genetic abnormalities and continuous stimulation of the NF-kappa B-IKK beta pathway are directly related to many types of inflammatory and autoimmune diseases, as well as to the genesis and survival of tumor cells. Objectives: Inhibition of the NF-kappa B-IKK beta cascade can be considered an attractive therapeutic method for the genesis of new prototypes to combat these chronic multifactorial diseases. Results: This review describes some prototypes and drugs that act to inhibit the NF-kappa B-IKK beta pathway, highlighting the realities, challenges and perspectives for therapeutic use. Conclusion: Although only proteasome inhibitors, such as bortezomib and carfilzomib, are a reality as therapeutically useful drugs among the known modulators of possible targets in the NF-kappa B-IKK beta pathway, some other prototypes described as IKK beta inhibitors have entered clinical stages as drug candidates for the control of inflammatory diseases. It is important to note that some classical drugs available on the pharmaceutical market, such as acetylsalicylic acid, were also described more recently as NF-kappa B pathway modulators as IKK beta inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据